LBL-033

N/A

Report date: 2026/03/19 17:22:26

Base Information

Drug NameLBL-033
Drug Alias NameLBL-033
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionMucin-16 inhibitorsCD3 T-cell engagers
TargetsMucin-16T cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A